The Causes of Deaths Occurred in Patients of Early Stage Laryngeal Cancer (Stage I, Stage II)

ObjectiveThe aim of the study was to investigate whether omentectomy (OMT) is necessary in the operation for apparently early stage malignant ovarian germ cell tumors (MOGCTs).Methods and MaterialsSearching medical records database of Sun Yat-sen University Cancer Center from January 1, 1966, to November 30, 2015, patients with MOGCTs were identified and their age, year of diagnosis, tumor grade, histologic subtype, International Federation of Gynecology and Obstetrics stage, nodal findings, gross observation of omentum, and performance of OMT were assessed. Overall survivals of patients with or without OMT were compared using Kaplan-Meier survival curves.ResultsA total of 223 MOGCT cases with clinically early stage (stage I and II) disease and with the 3 common histological subtypes of MOGCT were obtained, which include yolk sac tumor (YST), dysgerminoma (DSG), and immature teratoma (IMT). There were 192 stage I cases and 31 stage II cases. Fifty-four patients were diagnosed with YST, 61 with DSG, and 108 with IMT. Omentectomy was performed as part of the initial surgery in 74.0% patients (165/223) and was omitted in 26.0% patients (58/223). Chemotherapy was administered in 88.3% (197/223) of all patients. The median follow-up was 82.0 months. The 10-year overall survival rates of the patients with and without OMT were 90.5% and 98.1%, respectively (P = 0.156). Regarding different stages or histological subtypes, the 10-year survival rates of the 2 groups were 92.0% versus 97.9% (P = 0.324, stage I), 83.2% versus 100% (P = 0.351, stage II), 89.2% versus 100% (P = 0.303, YST), 94.1% versus 100% (P = 0.470, DSG), and 89.4% versus 96.0% (P = 0.405, IMT), respectively.ConclusionsIn conclusion, OMT in patients with clinically early stage MOGCT may not improve patient survival and may be omitted.

Download Full-text

Combination Chemotherapy (CVP or Chop)-Radiotherapy Approach in Early Stage Non-Hodgkin's Lymphomas

Tumori Journal ◽

10.1177/030089168206800207 ◽

1982 ◽

Vol 68 (2) ◽

pp. 137-142 ◽

Cited By ~ 3

Author(s):

Pasquale Comella ◽

Gianfranco Scoppa ◽

Giuseppe Abate ◽

Giuseppe Comella ◽

Gaetano Apice ◽

...

Keyword(s):

Combination Chemotherapy ◽

Early Stage ◽

Response To Therapy ◽

Stage I ◽

Stage Ii ◽

Actuarial Survival ◽

Favorable Histology ◽

Significant Difference ◽

Extended Field ◽

Hodgkin's Lymphomas

From January 1978 to December 1980, 42 patients with early stage non-Hodgkin's lymphoma other than of the gastrointestinal tract were treated with radiotherapy and combination chemotherapy. Eighteen patients in stage I were submitted to locally extended-field radiotherapy up to a mean dose of 48 Gy with a Co60 source and, after a 3-week rest period, to 6 cycles of combination chemotherapy. Twenty-four patients in stage II received 3 cycles of combination chemotherapy before and after irradiation, the same as for stage I. Combination chemotherapy consisted of cyclophosphamide, vincristine and prednisone (CVP) for 15 cases with favorable histology (3 NWDL, 1 NPDI, 11 DWDL), whereas it included cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for 27 cases with unfavorable histology (20 DPDL, 3 DM, 4 DH). Complete remission (CR) was achieved in 35/42 (83%) patients, with a highly significant difference between stage I (100%) and stage II (71%). After 42 months of follow-up, the probability of survival for all patients was 72%. Survival was better for stage I (88%) than for stage II (68%) and for favorable histology (87%) as compared to unfavorable histology (70%). Furthermore, survival was highly influenced by response to therapy. Indeed, actuarial survival rate for CR was 91% as compared to a median survival time of 10.2 months for the remaining patients. Four patients, all with poor histology, relapsed after 5–24 (mean 11) months of CR. Only one of them had an extension in extranodal sites and eventually died, despite the salvage treatment utilized. In our experience, locally extended-field irradiation combined with chemotherapy gave a high proportion of CR and seemed to prevent relapses, particularly in extranodal sites.

Download Full-text

Early-stage male breast cancer: A 10-year experience

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e11630 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e11630-e11630

Author(s):

N. Gercovich ◽

E. Gil Deza ◽

M. Russo ◽

C. Garcia Gerardi ◽

C. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Male Breast Cancer ◽

Ductal Carcinoma ◽

Early Stage ◽

Male Breast ◽

Stage I ◽

Stage Ii ◽

Breast Cancers ◽

Breast Cancer Patients

e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases. Objective: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008. Methods: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients. A database was designed following the recommendations of the Directors of Surgical Pathology of the USA. The information registered encompassed: adjuvant treatments, recurrence date and date of final consultation or death. Results: Twelve pts were identified. Mean age (range)= 66 yo (50–89 yo). Tumoral type= Invasive Ductal Carcinoma 12 pt. Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%). Nottingham´s grade= Grade 2: 8 pt, Grade 3: 3 pt, N/A=1 pt. Stage= I= 6 pt, II=6 pt. ER (Positve= 9 pt, Negative=1 pt, N/A= 2 pt). PR (Positve= 8 pt, Negative= 2 pt, N/A=2 pt). Her2neu (0+= 3 pt, 1+= 3 pt, 2+= 2 pt, N/A= 4 pt). Surgery= Mastectomy= 11 pt, Lumpectomy 1= pt. Radiotherapy=5 pt. Adjuvance= No=2 pt, Hormonotherapy (HT)= 3 pt, Chemotherapy (CHT) = 3 pt, CHT+HT= 4 pt. Recurrence= Yes= 2 pt, No= 10 pt. Survival: Dead= 1 pt, Alive =11 pt. Mean Time To Progression= Stage I =66 months, Stage II =42 months. Global survival: Stage I =66 months, Stage II =52 months. Conclusions: 1. Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM. 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3. Ten pt underwent adjuvant treatment. 4. With a mean follow up time of 60 months, all stage I patients are alive and there were no recurrences. Two of the 6 stage II pts progressed and one died. No significant financial relationships to disclose.

Download Full-text

Neuroendocrine carcinoma of the cervix: A single institution’s experience.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e15585 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e15585-e15585

Author(s):

Megan Preston ◽

Georgia Anne-Lee McCann ◽

David M. O'Malley ◽

Christina Boutsicaris ◽

Larry J. Copeland ◽

...

Keyword(s):

Adjuvant Therapy ◽

Metastatic Disease ◽

Survival Data ◽

Early Stage ◽

Stage I ◽

Stage Ii ◽

Advanced Stage ◽

Single Institution ◽

Early Stage Disease ◽

Stage Disease

e15585 Background: Neuroendocrine carcinomas (NEC) of the cervix comprise only 2% of all cervical cancers. As a result, prospective data is limited and treatment guidelines rely on literature from lung NEC. The objective of this study was to examine and report on our experience in the management of this rare, aggressive disease. Methods: This was an IRB-approved, single-institution, retrospective review. Study criteria included patients with cervical NEC diagnosed between 1990-2011. Demographic, treatment and survival data was collected. Progression-free survival (PFS) and overall survival (OS) was defined as the time from date of initial treatment until progression or death respectively, or date of last contact. Results: A total of 24 patients met inclusion criteria. The median age at diagnosis was 43. Median PFS was 13.6 months and median OS was 16.4 months. The majority of patients had advanced-stage disease (61% stage II-IV, 39% stage I). Of the 9 patients with stage I disease, 4 were treated with platinum + etoposide-based neoadjuvant chemotherapy and 5 were treated with initial radical surgery. Seven of the 9 patients had post-operative adjuvant therapy consisting of chemotherapy, chemo-radiation or radiation only. Seven of the 9 patients (78%) were alive at last follow-up. Of the two patients who were deceased, one had metastatic disease found at surgery and the other declined adjuvant therapy and died of recurrence. Patients with stage II-IV disease (n=15) had a median PFS and OS of 11.5 and 12.1 months, respectively. Only 2 had no evidence of disease at last encounter. The remainder died without achieving remission. Patients with metastatic disease had significantly worse survival when compared to those with loco-regional disease with a median OS of 8 vs. 28 months (p = .03), respectively. Conclusions: We report one of the largest single-institution experiences of neuroendocrine cervical cancer. Advanced-stage patients had a poor prognosis regardless of therapy. However, multi-modality therapy in early-stage disease resulted in an excellent prognosis (78% survival) for these rare, highly aggressive tumors. These findings support the goal of curative intent for early-stage disease using multi-modality therapy.

Download Full-text

An assessment of the impact of geographic variation on resection rates and survival for early-stage pancreatic adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15052 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15052-e15052

Author(s):

Bradley D. McDowell ◽

Brian J. Smith ◽

Anna M Button ◽

James R. Howe ◽

Elizabeth A. Chrischilles ◽

...

Keyword(s):

Pancreatic Cancer ◽

Overall Survival ◽

Pancreatic Adenocarcinoma ◽

Early Stage ◽

Stage I ◽

Stage Ii ◽

Survival Times ◽

Resection Rate ◽

Selection Factors ◽

The Impact

e15052 Background: Pancreatic resection is the only known curative option for pancreatic adenocarcinoma. Resection has been previously reported to be underutilized in patients with early stage disease. To develop a better understanding of this issue and control for treatment selection factors, we examined the relationship between geographic area resection rates and survival in patients with stage I/II pancreatic cancer. Methods: We queried Surveillance, Epidemiology, and End Results (SEER) data for patients with stage I/II cancer of the pancreatic head diagnosed from 2004-2009. We excluded patients with less than 3mo survival. Resection rates were calculated within Health Service Areas (HSAs) across all 18 SEER regions. Resection rate was defined as the number of patients who had an operation divided by the total number diagnosed with early stage pancreatic cancer. Multivariate Cox regression was used to estimate the overall survival effect of HSA rates while controlling for age, gender, marital status, poverty level, education, and AJCC stage. Results: 8,323 patients with stage I (n=1,454) and stage II (n=6,869) disease were analyzed. Pancreatectomy was performed in 476 patients (32.7%) with stage I disease and 3,846 (56.0%) with stage II disease. HSA resection rates were arranged into five groups (quintiles) which ranged from 42.7 to 65.7% (Table). Across the quintiles, median overall survival increased from 11 to 14 months, suggesting a positive association with resection rate. Multivariate analysis revealed that for every 10.00% increase in resection rate, the risk of overall death decreased by 5.26% (p<0.001). Conclusions: Patients with early stage pancreatic cancer who live in areas with higher resection rates have longer average survival times. Because geography should not influence treatment response, we conclude that efforts to raise resection rates should increase survival times in patients for whom there is uncertainty about the risk/benefits of resection. [Table: see text]

Download Full-text

Surgical treatment of the non-small cell lung cancer: Stage I (T1N0-T2N0) and stage II (T1N1-T2N1). Prognostic factors, results and recurrence

Lung Cancer ◽

10.1016/0169-5002(94)92245-4 ◽

1994 ◽

Vol 11 (5-6) ◽

pp. 437

Keyword(s):

Lung Cancer ◽

Prognostic Factors ◽

Surgical Treatment ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage I ◽

Stage Ii ◽

Cancer Stage ◽

Small Cell Lung

Download Full-text

Outcome of Asymptomatic Osteochondritis Dissecans of the Capitellum in Adolescent Baseball Players

Orthopaedic Journal of Sports Medicine ◽

10.1177/2325967117s00121 ◽

2017 ◽

Vol 5 (3_suppl3) ◽

pp. 2325967117S0012

Author(s):

Tetsuya Matsuura ◽

Toshiyuki Iwame ◽

Naoto Suzue ◽

Koichi Sairyo

Keyword(s):

Conservative Treatment ◽

Osteochondritis Dissecans ◽

Early Stage ◽

Stage I ◽

Stage Ii ◽

Radiological Outcome ◽

Loose Bodies ◽

Baseball Players ◽

Complete Repair

Objectives: Osteochondritis dissecans (OCD) of the capitellum is a well-recognized cause of elbow pain and disability in adolescent baseball players. OCD is classified into three different stages based on AP radiographs of the elbow in 45°flexion. Stage I was characterized by radiolucent areas. In stage II, nondisplaced fragments were present. Loose bodies and sclerotic change indicated stage III. Matsuura et al performed the conservative treatment on 101 patients with stage I or II lesions. Conservative treatment consisted of discontinuation of heavy use of the elbow for at least 6 months. Of 101 patients, 84 were diagnosed as stage I, with a mean age of 11.3 years and 17 were in stage II, with a mean age of 13.9 years. Of the 84 patients in stage I, healing was observed in 90.5%. In stage II, the incidence of healing decreased to 52.9%. Mean period required for healing was 14.9 months in stage I and 12.3 months in stage II. These results suggest that conservative treatment is recommended for the early stage lesions. However, little is known about the outcome of conservative treatment for asymptomatic OCD patients. The purpose of this study was to investigate 2year follow-up outcome of asymptomatic OCD in adolescent baseball players. Methods: We retrospectively reviewed 33 baseball players aged 9-12 years (mean, 11.3 years) with asymptomatic OCD. There were 23 stage I lesions and 10 stage II lesions. We recommended the conservative treatment including stop throwing to all the players. Sixteen players (48.5%) agreed to our advice. The remaining 17 players did not follow the authors’ advice. Twelve players (36.4%) changed position or throwing side and 5 players (15.1%) did not change throwing level. Two years later, subjects were evaluated clinically and radiographically. Radiological outcome was divided into 3 types, complete repair, incomplete repair, and failure. Results: Stop throwing produced complete repair in 93.7%, incomplete repair in 6.3%, and none of the failure. Changing position or throwing side produced complete repair in 41.7%, incomplete repair in 25%, and failure in 33.3%. Not changing throwing level produced complete repair in 20%, none of incomplete repair, and failure in 80% ( Table 1 ). Players with complete or incomplete repair had not any symptom at the follow-up. On the other hand, all the players with failure had symptom such as pain and/or catching. Six of 8 players (75%) with symptom needed operation. [Table: see text] Conclusion: Even in the asymptomatic early stage OCD, it is desirable to stop throwing until the healing is observed.

Download Full-text